Investigator Initiated, Prospective Study of Xenia Corneal Lenticule

Prospective, Investigator Initiated Feasibility Study to Evaluate the Safety, and Indicative Effectiveness of Gebauer™ Lenticules in Patients Suffering From Severe Keratoconus or Post LASIK Ectasia

Cornea ectatic conditions such as keratoconus and post-LASIK (Laser In situ Keratomileusis) ectasia are disorders of the eye that are notorious for its uncontrolled progression over time, leading to loss of vision. There are valuable treatment options for controlling disease progression in mild to moderate stages of such disease. However in advanced cases and / or when contact lenses cannot be worn, surgery remains the only treatment option to rehabilitate vision. Most treatment options are highly invasive and represent significant risks. This study evaluates a novel corneal implant, Gebauer™ Lenticule to treat severe keratoconus or post-LASIK ectasia. This implant is derived from porcine collagen and intended for intra-stromal insertion. The Gebauer™ Lenticule is expected to improve the stability of the cornea while not impairing the vision. The procedure is an additive procedure after other treatment options have been exhausted. The procedure is reversible with removal of the implant (in the unexpected case of an adverse reaction), and vision may be restored to baseline.

The purpose of this study is to evaluate how well the implant is tolerated, it's safety profile, and how effective this new treatment option is in the treatment of keratoconus or post-LASIK ectasia.

Study Overview

• Status: Recruiting
• Conditions: Keratoconus; Post-Laser Retinal Condition
• Intervention / Treatment: Device: Gebauer Lenticule

• Study Type: Interventional
• Enrollment (Estimated): 15
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: B Ilango; Phone Number: 01902307999; Email: balasubramaniam.ilango@nhs.net

Study Locations

• United Kingdom
  • West Midlands
    • Wolverhampton, West Midlands, United Kingdom, WV10 0QP
      • Recruiting
      • The Royal Wolverhampton NHS Trust
      • Contact: B Ilango; Phone Number: 01902307999; Email: balasubramaniam.ilango@nhs.net

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 79 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnosis of severe keratoconus in patients who would prefer to avoid corneal transplant surgery / penetrating keratoplasty OR
• Diagnosis of severe post-LASIK Ectasia in patients who would prefer to avoid corneal transplant surgery / penetrating keratoplasty
• In terms of general health, patients must be free of diagnosed terminal illnesses (life expectancy of greater than or equal to 2 years).
• Patients must be aged 18 years or over and less than 80 years old
• Patients' contact lenses must have been removed at least one-week prior to surgery for soft lenses and two weeks prior to surgery for hard lenses
• Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed
• Patient must be able and willing to complete all study visits and comply with the study-specific requirements

Exclusion Criteria:

• History or presence of any ocular pathologies that may interfere with the planned surgical treatment, including corneal epithelial problems
• Previous corneal transplantation or corneal implant in the designated eye
• Cataract with anticipated surgical intervention (IOL implantation) within 2 years
• Active inflammation and/or infection of the eye or the eye lid
• Patients with Intra Ocular Pressure (IOP) <10 mmHg or >21 mmHg
• Professionally diagnosed and currently treated autoimmune diseases
• Current strong symptoms of any allergy
• History of major organ transplantation and/or current continuing immunosuppressive treatment
• History of blood transfusion within the last 12 months
• Subject who is currently participating or has participated in another investigational clinical study within the past 60 days Pregnancy and lactation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Gebauer Lenticule; Gebauer Lenticule implant device	Device: Gebauer Lenticule; The Gebauer™ Lenticule corneal implant device is a custom-made device intended for patients suffering from keratoconus or post-LASIK ectasia. The device is expected to reinforce and stabilize the patient's cornea, so that a more consistent refraction is induced and a penetrating human cornea donor transplantation may be avoided or postponed.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with Immunological rejection by ophthalmic examination of Intraocular pressure, Best corrected visual acuity, Corneal and Lenticule transparency, Inflammation	Signs of immunological rejection during the post implantation observation period	6 months
Treatment-related adverse events.	The frequency and severity of all treatment-related adverse events, during implantation of the Gebauer™ Lenticule and throughout the post implantation observation period.	6 months
Changes in corneal topography (central K-reading results)	Changes in corneal topography (central K-reading results): at baseline vs. post implantation observation period	6 months
Central corneal thickness	Changes in central corneal thickness at baseline vs. post implantation corneal thickness (cornea plus lenticule)	6 months

Collaborators and Investigators

• Sponsor: The Royal Wolverhampton Hospitals NHS Trust
• Collaborators: Gebauer Company
• Investigators: Principal Investigator: B Ilango, The Royal Wolverhampton NHS Trust

Study record dates

Study Major Dates

• Study Start (Actual): May 15, 2024
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: February 2, 2021
• First Submitted That Met QC Criteria: February 2, 2021
• First Posted (Actual): February 5, 2021

Study Record Updates

• Last Update Posted (Actual): January 15, 2026
• Last Update Submitted That Met QC Criteria: January 13, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Corneal Diseases; Keratoconus
• Other Study ID Numbers: 2019OPH108

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No